
Dyslipidemia
Latest News
CME Content



Depressed elderly patients undergoing SAVR or TAVR had a 7.3% higher rate of mortality compared to non-depressed patients.

Varenicline (Chantix) increases patients’ risk of an emergency department visit or hospitalization for a cardiovascular event by 34%.

Kevin Maki, PhD, discussed the impact that the new guidelines for hypertension from the AHA and the ACC will have on patients and physicians.

Renova Therapeutics is planning a 536-patient phase 3 trial, FLOURISH, to begin in early 2018.

Kevin Maki, PhD, discussed the current state of lipid care in the United States.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

The smart strap is the first medical accessory for a smartwatch to receive FDA approval.





ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.

Praluent can help patients with clinical ASCVD or HeFH

Pitavastatin is superior to pravastatin in reducing LDL in patients with HIV.

Certain conditions are linked to multiple sclerosis disease progression.

Breakthrough status for a new drug to treat familial hypercholesterolemia.

Steven Nissen, MD, says that heart attacks in fit people are not unusual.

Systemic atherosclerosis causes peripheral artery disease, and these patients are at risk of cardiovascular death and stroke.

Do patients diagnosed with anxiety disorder experience a greater burden of metabolic disorders such as diabetes and hyperlipidemia?



































































